精神分裂症的智能手机干预应用：学术文献和应用商店综述

IF 3.5 2区医学 Q1 PSYCHIATRY

Schizophrenia Research Pub Date : 2025-10-03 DOI:10.1016/j.schres.2025.09.007

Winna Xia , Christine Hau , James Burns , Sean Ryan , Joseph Firth , Jake Lineradon , John Torous

{"title":"精神分裂症的智能手机干预应用：学术文献和应用商店综述","authors":"Winna Xia , Christine Hau , James Burns , Sean Ryan , Joseph Firth , Jake Lineradon , John Torous","doi":"10.1016/j.schres.2025.09.007","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>While the interest and use of apps for anxiety and depression accelerated with COVID-19, less is known about the status of apps for people with schizophrenia and psychosis-spectrum disorders. This study aims to offer a comprehensive overview of the research and commercial app marketplaces (Apple, Android) to assess how recent technological advances translate into tools patients can use today.</div></div><div><h3>Methods</h3><div>In December 2024, we conducted a narrative review for apps related to schizophrenia and coded a brief overview of the studies, eligibility, outcomes and experiences, engagement and features, attrition and adherence, and app availability. We simultaneously conducted a search on the U.S. Google Play and the U.S. Apple App Store for apps denoted in the research literature and other commercially available apps.</div></div><div><h3>Results</h3><div>The academic literature search yielded 3753 articles, of which 34 were included. Across these 34 studies, 32 unique apps related to schizophrenia and psychosis were featured. A search of the U.S. app marketplaces yielded only one relevant app peer-reviewed in the last decade and that was broadly accessible to patients.</div></div><div><h3>Conclusion</h3><div>To realize the full clinical utility of these apps, it is essential to shift the focus toward their specific features and functionalities, supported by more rigorous research and follow-up studies. There is a pressing need for greater standardization in outcome measures and record-keeping practices to ensure consistency and reliability across the field. While the number of commercially available apps has increased, the lack of robust, large-scale controlled studies and standardized controls has resulted in inconsistent findings. Findings highlight the importance of conducting more controlled studies and randomized clinical trials with appropriate controls to strengthen the evidence base and guide the effective implementation of digital health interventions in mental health care.</div></div>","PeriodicalId":21417,"journal":{"name":"Schizophrenia Research","volume":"285 ","pages":"Pages 204-214"},"PeriodicalIF":3.5000,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Smartphone intervention apps for schizophrenia: A review of the academic literature and app stores\",\"authors\":\"Winna Xia , Christine Hau , James Burns , Sean Ryan , Joseph Firth , Jake Lineradon , John Torous\",\"doi\":\"10.1016/j.schres.2025.09.007\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>While the interest and use of apps for anxiety and depression accelerated with COVID-19, less is known about the status of apps for people with schizophrenia and psychosis-spectrum disorders. This study aims to offer a comprehensive overview of the research and commercial app marketplaces (Apple, Android) to assess how recent technological advances translate into tools patients can use today.</div></div><div><h3>Methods</h3><div>In December 2024, we conducted a narrative review for apps related to schizophrenia and coded a brief overview of the studies, eligibility, outcomes and experiences, engagement and features, attrition and adherence, and app availability. We simultaneously conducted a search on the U.S. Google Play and the U.S. Apple App Store for apps denoted in the research literature and other commercially available apps.</div></div><div><h3>Results</h3><div>The academic literature search yielded 3753 articles, of which 34 were included. Across these 34 studies, 32 unique apps related to schizophrenia and psychosis were featured. A search of the U.S. app marketplaces yielded only one relevant app peer-reviewed in the last decade and that was broadly accessible to patients.</div></div><div><h3>Conclusion</h3><div>To realize the full clinical utility of these apps, it is essential to shift the focus toward their specific features and functionalities, supported by more rigorous research and follow-up studies. There is a pressing need for greater standardization in outcome measures and record-keeping practices to ensure consistency and reliability across the field. While the number of commercially available apps has increased, the lack of robust, large-scale controlled studies and standardized controls has resulted in inconsistent findings. Findings highlight the importance of conducting more controlled studies and randomized clinical trials with appropriate controls to strengthen the evidence base and guide the effective implementation of digital health interventions in mental health care.</div></div>\",\"PeriodicalId\":21417,\"journal\":{\"name\":\"Schizophrenia Research\",\"volume\":\"285 \",\"pages\":\"Pages 204-214\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2025-10-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Schizophrenia Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0920996425003172\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PSYCHIATRY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Schizophrenia Research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0920996425003172","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}

引用次数: 0

摘要

随着COVID-19的出现，人们对应用程序治疗焦虑和抑郁的兴趣和使用加速了，但人们对应用程序治疗精神分裂症和精神病谱系障碍患者的状况知之甚少。本研究旨在全面概述研究和商业应用程序市场（Apple, Android），以评估最近的技术进步如何转化为患者今天可以使用的工具。方法在2024年12月，我们对与精神分裂症相关的应用程序进行了叙述性回顾，并对研究、资格、结果和经验、参与度和特征、流失和依从性以及应用程序可用性进行了简要概述。我们同时在美国谷歌Play和美国苹果应用商店搜索研究文献中提到的应用和其他商业应用。结果共检索学术文献3753篇，其中纳入34篇。在这34项研究中，有32个与精神分裂症和精神病相关的独特应用程序。对美国应用程序市场的搜索显示，在过去十年中，只有一个相关的应用程序经过同行评审，而且患者可以广泛使用。结论为了充分发挥这些应用程序的临床效用，必须将重点转移到它们的具体特征和功能上，并通过更严格的研究和后续研究来支持。迫切需要在结果衡量和记录保存做法方面加强标准化，以确保整个领域的一致性和可靠性。虽然商业应用程序的数量有所增加，但由于缺乏可靠的大规模对照研究和标准化控制，导致研究结果不一致。研究结果强调了开展更多对照研究和具有适当对照的随机临床试验的重要性，以加强证据基础，并指导在精神卫生保健中有效实施数字卫生干预措施。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Smartphone intervention apps for schizophrenia: A review of the academic literature and app stores

Background

While the interest and use of apps for anxiety and depression accelerated with COVID-19, less is known about the status of apps for people with schizophrenia and psychosis-spectrum disorders. This study aims to offer a comprehensive overview of the research and commercial app marketplaces (Apple, Android) to assess how recent technological advances translate into tools patients can use today.

Methods

In December 2024, we conducted a narrative review for apps related to schizophrenia and coded a brief overview of the studies, eligibility, outcomes and experiences, engagement and features, attrition and adherence, and app availability. We simultaneously conducted a search on the U.S. Google Play and the U.S. Apple App Store for apps denoted in the research literature and other commercially available apps.

Results

The academic literature search yielded 3753 articles, of which 34 were included. Across these 34 studies, 32 unique apps related to schizophrenia and psychosis were featured. A search of the U.S. app marketplaces yielded only one relevant app peer-reviewed in the last decade and that was broadly accessible to patients.

Conclusion

To realize the full clinical utility of these apps, it is essential to shift the focus toward their specific features and functionalities, supported by more rigorous research and follow-up studies. There is a pressing need for greater standardization in outcome measures and record-keeping practices to ensure consistency and reliability across the field. While the number of commercially available apps has increased, the lack of robust, large-scale controlled studies and standardized controls has resulted in inconsistent findings. Findings highlight the importance of conducting more controlled studies and randomized clinical trials with appropriate controls to strengthen the evidence base and guide the effective implementation of digital health interventions in mental health care.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Schizophrenia Research 医学-精神病学

CiteScore

7.50

自引率

8.90%

发文量

429

审稿时长

10.2 weeks

期刊介绍： As official journal of the Schizophrenia International Research Society (SIRS) Schizophrenia Research is THE journal of choice for international researchers and clinicians to share their work with the global schizophrenia research community. More than 6000 institutes have online or print (or both) access to this journal - the largest specialist journal in the field, with the largest readership! Schizophrenia Research''s time to first decision is as fast as 6 weeks and its publishing speed is as fast as 4 weeks until online publication (corrected proof/Article in Press) after acceptance and 14 weeks from acceptance until publication in a printed issue. The journal publishes novel papers that really contribute to understanding the biology and treatment of schizophrenic disorders; Schizophrenia Research brings together biological, clinical and psychological research in order to stimulate the synthesis of findings from all disciplines involved in improving patient outcomes in schizophrenia.